Cargando…
ESA, Iron Therapy and New Drugs: Are There New Perspectives in the Treatment of Anaemia?
Anemia is a well-known consequence of chronic kidney disease (CKD); it is mainly due to a relative insufficiency of erythropoietin synthesis by the failing kidneys. Over the years, the combination of erythropoiesis stimulating agents (ESA) and iron has become the standard of care of anemia. All ESAs...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922992/ https://www.ncbi.nlm.nih.gov/pubmed/33670704 http://dx.doi.org/10.3390/jcm10040839 |